微型染色体维持蛋白2在膀胱移行细胞癌中的表达及临床意义

The research on expression and clinical significance of MCM2 in BTCC

背景与目的:目前研究己经证实,微型染色体维持蛋白2(minichromosome maintenance protein2,MCM2)是细胞周期阶段的特异性标志物,在进入细胞周期的细胞中均有表达,但在分化成熟的细胞及静止期细胞中不表达。因此,在增殖发育异常和突变的细胞中,MCM2可作为细胞增殖标志物标记细胞所处的状态,作为一些异型病变和肿瘤的诊断工具。本研究探讨MCM2在膀胱移行细胞癌中的表达及其临床意义。方法:应用免疫组织化学方法检测42例膀胱移行细胞癌与12例良性前列腺增生患者的正常膀胱黏膜中MCM2的表达,以统计学方法分析其表达与临床生物学特性之间的关系,并与Ki-67的表达相比较。结果:MCM2在癌组织中阳性率为100%(42/42),12例正常膀胱黏膜中均呈阴性表达,两组间差异有显著性(P<0.01)。MCM2在膀胱移行细胞癌中的表达与患者年龄、性别及临床分期无明显相关性(P>0.05),而与肿瘤的病理分级密切相关(P<0.05)。癌组织中MCM2阳性率(100%)与Ki-67阳性率(85.7%)之间差异有显著性(P<0.05)。结论:MCM2是比Ki-67更好的细胞增殖标志物,是膀胱癌细胞的更好标志和分级指标。

Background and purpose： It is verified that MCM2 is a specific marker in the cell cycle,and expressed in all cells entering into the cycle, however, no expression is found in the differentiated cells and static period cell. Therefore, in the abnormally proliferative developmental cells and mutagenic cells,MCM2 could be used to mark the status of the cells as a cellular proliferative marker, and then to be a diagnostic tool for some heterotypical pathological changes and tumors.Our study demonstrated that the expression and clinical significance of MCM2 in bladder transitional cell cancer （BTCC）. Methods： The expression of MCM2 was examined by immunohistochemistry Streptavidin-Peroxidase method in 12 cases of normal bladder tissues and 42 cases of BTCC. Results： The positive expression of MCM2 in BTCC was 100%, whereas in normal tissues, no positive expression was found （P〈0.05）. The expression of MCM2 did not show correlation to sex, age and tumor stage （P〉0.05）. The expression of MCM2 was closely associated with tumor pathological grade （P〈0.05）. There was significant difference between the positive expression of MCM2 and Ki-67 in BTCC （P〈0.05）. Conclusion： Compared with Ki-67, MCM2 is a better marker of tumor cell proliferation and may be a better marker and grade index.